Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and ...

The $74.5 million grant will fund a study focused on an inherited genetic mutation that has been linked to Alzheimer's.

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Today, the first monoclonal antibodies, lecanemab and donanemab, are available, showing that their reduction effect on these ...

Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

NICE has said it expects to evaluate dozens of potential treatments for Alzheimer’s disease over the next few years. Elisabeth Mahase examines what we know about these drugs This year the National ...

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...